HitGen Inc. (SHA:688222)

China flag China · Delayed Price · Currency is CNY
27.89
+1.56 (5.92%)
At close: Apr 29, 2026
87.43%
Market Cap 10.52B
Revenue (ttm) 525.57M
Net Income (ttm) 114.02M
Shares Out 399.44M
EPS (ttm) 0.28
PE Ratio 94.04
Forward PE 84.94
Dividend 0.06 (0.23%)
Ex-Dividend Date n/a
Volume 28,055,246
Average Volume 19,603,570
Open 27.64
Previous Close 26.33
Day's Range 26.76 - 28.68
52-Week Range 13.93 - 42.98
Beta 0.54
RSI 56.40
Earnings Date Apr 29, 2026

About HitGen

HitGen Inc. operates as a drug discovery research platform for small molecules and nucleic acid drugs in China and internationally. Its technology platform includes DNA-encoded library technology; fragment-based drug discovery and structure-based drug design technologies; emerging technology platforms for synthetic therapeutic oligonucleotide technology; and targeted protein degradation technology. The company’s product pipeline also includes HG146, a selective HDAC inhibitor for multiple myeloma and solid tumor; HG030, a second generation NTRK... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 492
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688222
Full Company Profile

Financial Performance

In 2025, HitGen's revenue was 525.57 million, an increase of 23.09% compared to the previous year's 426.99 million. Earnings were 114.02 million, an increase of 122.01%.

Financial Statements

News

There is no news available yet.